AcuCort publicerade den 28 april sin första kvartalsrapport för år 2022.
Q1 report exceeding both our and cons. expectations Terra was the shining star with adj.
H&D Wireless intäkter i kv1 2022 blev ca 27 procent lägre än vår prognos.
Redeye ceases its coverage of Nanologica due to the end of the contractual period.
Fortsatt förbättring av marginalen Sensys Gatso redovisade en omsättning på 113 mkr (107) och EBITDA...
Stark marginal i Q1'22 Embellence Group rapporterade EBITA om 32,8 mkr i Q1'22, upp från 28,2 mkr i ...
Försäljningstillväxt 64% y/y Försäljningen uppgick till 53,1 mkr vs vårt estimat om 43,6 mkr.
Redeye was hoping for a bit more in terms of sales given the strong growth trend during the second h...
Redeye retains its positive view on Sdiptech following a Q1 report in line with our expectations.
Redeye retains its positive stance towards Vertiseit following a Q1 report beating our forecasts reg...
Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes seve...
Redeye maintains its fair value range unchanged – the quarterly financials were in line with expecta...
Redeye argues that the changed financial target is relatively unaffecting the long-term case for Sed...
Redeye’s preliminary revisions suggest adjustments to Hoylu’s 2022E and 2023E, as its Q1’22 figures ...
Adj. Q1 sales +79% q-o-q and +45% vs. ABGSCe… …but lower gross margins than expected Ovzon-3 to be l...
Redeye changes its sales forecast and fair value range after weaker-than-expected sales for Q1 while...
Enersense’s Q1 profitability figures beat our estimates but cost inflation can hurt figures more dur...
Exel’s EBIT appears bound to improve more from the recent lows.
Strong Q1’22 beat – revenues 54% higher than cons. New orders in Q1, driven by higher-margin segment...
Solid operational performance and project progress +100bps interest rate to our ’24e impacts CEPS by...
